Bedford and APP Pharmaceuticals have announced a shortage of vinblastine sulfate for injection due to manufacturing delays. To help address this shortage, APP will be releasing a single lot of vinblastine sulfate with a shortened shelf of life of 6 months. At this time, Bedford has not announced an availability date for its vinblastine sulfate product.
Vinblastine sulfate is an antimicrotubule agent indicated for the treatment of a number of different cancers including Hodgkin’s disease, Kaposi’s sarcoma, and breast cancer.
For more information call APP at (888) 386-1300, Bedford at (800) 562-4797, or visit www.fda.gov/cder/drug/shortages/default.htm#Vinblastine.